Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Renal Cell 8Sarcoma 7Sarcoma, Clear Cell 2Neurofibrosarcoma 2Nerve Sheath Neoplasms 2Neoplasm Metastasis 2Liposarcoma 2Kidney Neoplasms 2Histiocytoma, Angiomatoid Fibrous 2Granuloma, Plasma Cell 2Glioblastoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Vascular Neoplasms 1Solitary Fibrous Tumors 1Solid Neoplasm 1Smooth Muscle Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Refractory or Recurrent Solid Tumor 1Perivascular Epithelioid Cell Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Liposarcoma, Myxoid 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1

Interventions

Radiosurgery 50Magnetic Resonance Spectroscopy 34Temozolomide 28Bevacizumab 24pembrolizumab 23Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7Blood Specimen Collection 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Lomustine 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × pazopanib × 1 year × Clear all
NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
35 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡